Using Novel Imaging to More Safely Treat Neuroendocrine Tumors

Part of paid clinical trials in Madison, Wisconsin.

Sponsor
University of Wisconsin, Madison
Study ID
NCT06122610
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT) — DEVICE
    SPECT/CT will be performed after first cycle of Lutathera® treatment
  • Photon Emission Tomography / CT (PET/CT) — DEVICE
    PET/CT will be performed after 64Cu-DOTATATE and Lutathera® treatment
  • 64Cu-Dotatate — DRUG
    Standard of care administration of radioactive drug for PET/CT
  • 177Lu-Dotatate — DRUG
    Standard of care administration of radioactive drug for PET/CT and SPECT/CT

Study Details

The goal of this research is to determine if DetectnetTM PET/CT can be used to make Lutathera therapy safer for patients with neuroendocrine cancer. Participants will: * Complete two phases involving 6 visits * Undergo additional research PET/CT, and possibly SPECT/CT scans

Key Dates

Start date
Mar 7, 2025
Status verified
Mar 2026
Primary completion
Jun 30, 2026
Completion
Jun 30, 2026

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Participants treated with Lutathera

Primary Outcome Measure

Compare pre-therapy and post-therapy voxel-based dosimetry estimates [ Time Frame: Baseline and 120 hours post-dose ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Wisconsin - MadisonMadisonWisconsin53705-

Find similar trials in Madison, WI

By condition
Neuroendocrine tumors
By specialty
Oncology
By research site
University of Wisconsin - Madison· Madison, WI

Related Studies